Clinical trial · Observational
Feasibility of Saliva and Remote Monitoring of Active Cytomegalovirus (CMV) Infection and Symptoms During Ovarian Cancer Treatment
NCT06870539CI-TRIAL-00098422completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluates the feasibility and accuracy of using saliva to remotely monitor cytomegalovirus (CMV) infection in individuals receiving treatment for ovarian cancer.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer-related Cognitive Dysfunction | — | UNRESOLVED | — |
| Cytomegaloviral Infection | — | UNRESOLVED | — |
| Fallopian Tube Carcinoma | Fallopian Tube Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Ovarian Carcinoma | Ovarian Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Primary Peritoneal Carcinoma | Primary Peritoneal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Non-Interventional Study | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational
- description
- Patients undergo saliva sample collection as well as in-clinic or at-home blood sample collection on study. Patients also complete questionnaires, undergo cognitive function testing, and have their medical records reviewed on study.
- interventionNames
- Other: Non-Interventional Study
Primary outcomes (1)
- measure
- Using saliva and blood samples to remotely monitor cytomegalovirus (CMV) infection
- timeFrame
- Baseline
- description
- Assessed through collection and comparison of blood and saliva samples collected from individuals receiving treatment for ovarian cancer. Samples may be collected in clinic or at home following study enrollment. Saliva will be self-collected using Oragene OGR-600 kits. Blood samples will be collected at the time of another scheduled clinic blood draw (Aim 1) or at home through a home phlebotomy service (Aim 2).
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 * Ability to read and write in English * Diagnosed with ovarian cancer (ovarian, primary peritoneal, fallopian tube) * Receiving care from providers at Mayo Clinic * Regardless of diseases status, actively receiving treatment for ovarian cancer (frontline, maintenance, progression, recurrence) Exclusion Criteria: * Pregnant at the time of study participation * Inability to provide informed written consent * History of dementia, stroke, brain tumors or other condition which may impair cognitive functioning
References
Publications (0)
Data not yet available
No reference posted for this study.